Tyk2 Active Human Recombinant Protein
- Known as:
- Tyk2 Active Human Recombinant Protein
- Catalog number:
- 40285
- Product Quantity:
- 10 µg
- Category:
- -
- Supplier:
- Biotech support group
- Gene target:
- Tyk2 Active Human Recombinant Protein
Related genes to: Tyk2 Active Human Recombinant Protein
- Gene:
- TYK2 NIH gene
- Name:
- tyrosine kinase 2
- Previous symbol:
- -
- Synonyms:
- JTK1
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-09-10
- Date modifiied:
- 2019-04-23
Related products to: Tyk2 Active Human Recombinant Protein
Related articles to: Tyk2 Active Human Recombinant Protein
- Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic Inflammatory Bowel Diseases (IBD) characterized by complex immune dysregulation and multifactorial pathogenesis. Conventional therapies often show limited efficacy and are associated with substantial adverse effects. This review highlights recent advancements in targeted molecular therapies for IBD, emphasizing biologics, small molecules, and emerging delivery technologies. - Source: PubMed
Publication date: 2026/06/09
Borra Praveen KumarChandra PhoolRaghav ArvindKoneru AnupamaSachan NeetuGautam Manish Kumar - Tyrosine kinase 2 (TYK2) is a genetically defined target for autoimmune disease, with first-generation inhibitors showing clinical success in some but not all associated indications. A deeper understanding of TYK2 structure-function relationships, protein-ligand interactions, and the impact of human variants could inform next-generation therapeutics. Here, we applied deep mutational scanning (DMS) to assess >23,000 amino acid substitutions across two TYK2 functions: interferon alpha (IFN-α) signaling and protein abundance. This enabled high-resolution structure-function mapping and the identification of novel allosteric sites. By coupling DMS with inhibitor treatment, we uncovered variants that modulate compound potency. We also show that human variants - both common and rare - that are protective against autoimmune phenotypes reduce TYK2 protein abundance. Together, these findings demonstrate that DMS can prospectively reveal novel druggable sites, clarify structure-activity relationships (SAR), and highlight TYK2 degradation as a potential therapeutic strategy in autoimmunity. - Source: PubMed
Publication date: 2026/06/10
Howard Conor JAbell Nathan SWarneford-Thomson Robert RMahdavi EdenSu Alan LResnick CarmenMohammed NabilThompson Erin MHolzinger Emily RCatalano KatrinaHukku AbhayMintier Gabriel AMacKenzie MorganJiang Bryan LBarbosa Rabago DoraChan AngelaNtimi CarolindahWeiler Kaitlyn NWilson Stephen CMaranville Joseph CSheth Payal RPlenge Robert MKosuri SriramDickel Diane E - There is a dynamic accommodation between the maternal immune system and conceptus, including the thymus and lymph nodes, during early pregnancy. Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is involved in early placentation. However, it was not fully understood that early pregnancy had effects on JAK/STAT signaling pathway in the thymus and lymph nodes of ewes. In this study, thymuses and lymph nodes of ewes were collected at day 16 of the estrous cycle (N16), and at days 13, 16, and 25 of gestation (G13, G16, and G25). Expressions of mRNA and protein of JAK/STAT members, including interferon α/β receptor 1 (IFNAR1), JAK1, tyrosine kinase 2 (TYK2), STAT3, interferon regulatory factor 9 (IRF9), B-cell lymphoma-extra large (BCL-XL), BCL-2, myelocytomatosis viral oncogene homolog (c-Myc), and p21 (a protein with a molecular weight of 21 kDa), were analyzed. The results indicated that there were increases in mRNA and protein expression of p-IFNAR1, p-JAK1, TYK2, p-STAT3, IRF9, and p21 in the thymus, and p-STAT3 and BCL-XL in lymph nodes. In addition, expression levels of p-IFNAR1 and p-JAK1 in the thymus and c-Myc in lymph nodes peaked at G16, but expression levels of c-Myc, BCL-XL, BCL-2, and P21 peaked at G13 in the thymus. Furthermore, expression levels of TYK2 and p-STAT3 in the thymus and p-JAK1, TYK2, and P21 in lymph nodes were higher at G16 and G25. P21 and p-IFNAR1 peaked at G25, but IRF9 peaked at N16. BCL-2 level was greater at N16 and G25. In summary, early pregnancy modulated JAK/STAT signaling pathway in the maternal thymus and lymph nodes in a pregnancy-stage- and tissue-specific manner, which may be associated with the establishment of maternal immune tolerance during early pregnancy in ewes. - Source: PubMed
Publication date: 2026/06/08
Wu ChenxuLi JingjingZhang YaqiShi QianqianZhang LeyingYang Ling - HL-300 is a novel topical pan-JAK inhibitor targeting JAK1, JAK2, JAK3, and TYK2 for atopic dermatitis (AD). This first-in-human study evaluated its safety, tolerability, and pharmacokinetics (PK) in healthy Chinese adults. - Source: PubMed
Publication date: 2026/06/09
Qiu HuiZhang XingfeiHuang JieYe LinZou ChanXie JinlianDeng KunhongWu QianHe XiulinLiang CongxinLiu YongYang GuangYang GuopingGuo Chengxian - - Source: PubMed
Publication date: 2026/06/05
Sood SiddharthaBagit AhmedMaliyar KhaladRankin Brian DAbduelmula AbrahimRimke AlexanderGeorgakopoulos Jorge RLeung FernejoyDevani Alim RMufti AsfandyarPrajapati Vimal HVender RonaldYeung Jensen